ADVERTISEMENT
Mark Pegram, MD, Discusses the HER2CLIMB Trial and Promising Nature of Tucatinib Therapy
01/10/2020
Dr Pegram spoke about the basis, findings, and clinical significance of the HER2CLIMB trial examining tucatinib therapy for HER2-positive breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement